News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.
Quanterix said that the acquisition will secure the supply of neurofilament light antibodies that are critical to its Simoa assays and services.
The company is aiming to create a suite of products that can help researchers and manufacturers engineer various genomes at scale for multiple purposes.
The company said that it will use the funds to commercialize its IsoLight platform for use in quality control and guidance of CAR T therapy.
The agreement follows a number of other distribution deals Bioké has signed in recent months including ones with Omni Life Science, Syntec, and Namocell.
New instrumentation, reagents, and methods, as well as increasing interest in small and single-cell samples, could prove a boon for the technology.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.